ACT's Occlusion Perfusion Catheter Licensed to Toray for Peripheral Stenosis and Restenosis Treatment

April 19, 2016—Advanced Catheter Therapies, Inc. (ACT) announced that it has signed a worldwide license agreement with Toray Industries, Inc. to manufacture, market, and sell ACT’s Occlusion Perfusion Catheter (OPC), as a targeted therapeutic agent delivery system for the treatment of peripheral vascular stenosis and restenosis. The OPC has been cleared by the US Food and Drug Administration.

According to the company, the OPC is a multilumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the targeted delivery of various therapeutic and diagnostic agents to the peripheral vasculature. It has the ability to create a localized treatment chamber and place the agent circumferentially into the vasculature of the treatment chamber. Inflow and outflow ports allow for chamber filling, evacuation, and flushing. Additionally, the OPC is able to measure pressure applied inside the treatment chamber. Clinicians can select the agent and volume, as well as limit systemic release of the agent, noted ACT.

Terms of the licensing agreement were not disclosed. ACT began manufacturing the OPC approximately 1 year ago to support clinical trials and a targeted test market release. The OPC remains available for licensing within other fields such as coronary stenosis and restenosis, oncology, dialysis, venous insufficiency and lytic therapy, advised the company.